His primary areas of investigation include Multiple sclerosis, Internal medicine, Immunology, Surgery and Placebo. His Multiple sclerosis study combines topics in areas such as Central nervous system disease, Disease, Pathology, Intensive care medicine and Physical therapy. His work deals with themes such as Gastroenterology, Expanded Disability Status Scale and Oncology, which intersect with Internal medicine.
His work in Immunology tackles topics such as Standardized mortality ratio which are related to areas like Retrospective cohort study. The study incorporates disciplines such as Stroke, Spinal cord compression and Anesthesia in addition to Surgery. His Placebo research is multidisciplinary, incorporating elements of Clinical endpoint, Randomized controlled trial, Clinical trial and Hazard ratio.
Per Soelberg Sørensen mostly deals with Multiple sclerosis, Internal medicine, Immunology, Disease and Expanded Disability Status Scale. In his study, White matter is inextricably linked to Pathology, which falls within the broad field of Multiple sclerosis. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Placebo, Surgery and Oncology.
Per Soelberg Sørensen interconnects Cladribine, Adverse effect, Randomized controlled trial and Clinical trial in the investigation of issues within Placebo. As part of his studies on Immunology, Per Soelberg Sørensen often connects relevant subjects like Central nervous system. His Natalizumab research includes elements of Fingolimod and Glatiramer acetate.
Multiple sclerosis, Internal medicine, Disease, Expanded Disability Status Scale and Cladribine are his primary areas of study. Per Soelberg Sørensen combines Multiple sclerosis and In patient in his studies. The various areas that Per Soelberg Sørensen examines in his Internal medicine study include Placebo and Oncology.
His study in the fields of Demyelinating disease under the domain of Disease overlaps with other disciplines such as Multidisciplinary approach. His Expanded Disability Status Scale study incorporates themes from Interquartile range, Cognition, Proportional hazards model, Propensity score matching and Hazard ratio. His study in Cladribine is interdisciplinary in nature, drawing from both Magnetic resonance imaging, CLARITY and Immune system.
Per Soelberg Sørensen mainly investigates Multiple sclerosis, Internal medicine, Cladribine, Placebo and Confidence interval. His studies in Multiple sclerosis integrate themes in fields like Clinical trial, Pharmacological treatment, Guideline, Intensive care medicine and Disease. His studies deal with areas such as Dimethyl fumarate, Genotyping, Human leukocyte antigen and Interferon beta as well as Internal medicine.
The concepts of his Cladribine study are interwoven with issues in Immune system, Magnetic resonance imaging and Oncology. His work carried out in the field of Placebo brings together such families of science as Gastroenterology and Randomized controlled trial. Per Soelberg Sørensen has researched Confidence interval in several fields, including Expanded Disability Status Scale, Epidemiology, Proportional hazards model and Cohort study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson;Brenda L. Banwell;Frederik Barkhof;Frederik Barkhof;William M. Carroll.
Lancet Neurology (2017)
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Stephen Sawcer;Garrett Hellenthal;Matti Pirinen;Chris C. A. Spencer.
Defining the clinical course of multiple sclerosis: The 2013 revisions
Fred D. Lublin;Stephen C. Reingold;Jeffrey A. Cohen;Gary R. Cutter.
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.
Giancarlo Comi;Massimo Filippi;Frederik Barkhof;Luca Durelli.
The Lancet (2001)
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Josa M. Frischer;Stephan Bramow;Assunta Dal-Bianco;Claudia F. Lucchinetti.
The Changing Demographic Pattern of Multiple Sclerosis Epidemiology
Nils Iørgen Koch-Henriksen;Per Soelberg Sørensen.
Lancet Neurology (2010)
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
Ashley H. Beecham;Nikolaos A. Patsopoulos;Nikolaos A. Patsopoulos;Dionysia K. Xifara;Mary F. Davis.
Nature Genetics (2013)
Remyelination is extensive in a subset of multiple sclerosis patients
Peter Patrikios;Christine Stadelmann;Alexandra Kutzelnigg;Helmut Rauschka.
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Gavin Giovannoni;Giancarlo Comi;Stuart Cook;Kottil Rammohan.
The New England Journal of Medicine (2010)
Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood.
Anders Koch;Mads Melbye;Per Sørensen;Preben Homøe.
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: